Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Precision BioSciences Inc DTIL

Healthcare Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate... see more

Current News (NDAQ:DTIL)

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Business Wire 12 hours ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 23, 2025

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Business Wire November 19, 2025

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Business Wire November 10, 2025

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Business Wire November 10, 2025

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Business Wire November 3, 2025

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Business Wire October 31, 2025

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Business Wire October 14, 2025

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Business Wire October 9, 2025
View More News ››

Opinion & Analysis (NDAQ:DTIL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DTIL)

Using technical analysis for this stock.

It is signalling a big upswing for shareholders this morning anyway
coolfooldumbguy - June 25, 2025

Buy buddy buy.

What are you guys out there waiting for,the stock price is in an uptrend already today,so that you better get on board with this one,or...
coolfooldumbguy - January 10, 2025

BUY BUY BUY BUY BUY

Looking great now with that revamp float
Nibinator - February 15, 2024
View more Bullboard ››

TomaGold Corp.

TomaGold Corp.

TomaGold Corporation, together with its subsidiaries, engages in the acquisition, exploration, assessment, and development of ...
View More »

Podcasts